CBGA

Cronos Group and Ginkgo Bioworks Announce Achievement of Equity Milestone in Partnership to Produce Cultured Cannabinoids

Retrieved on: 
Monday, August 23, 2021
Ix, Fifth Avenue, Cannabinoid, U.S. Securities and Exchange Commission, Adoption, Nature, Intention, SEC, Transaction, CBGA, Attention, Person, Risk, Forward-looking statement, Mission statement, EDGAR, Synthetic biology, Reading, Proxy, Failure, Partnership, SEDAR, CBG, Sale, Phrase, Security (finance), Risk management

All information that is not clearly historical in nature may constitute Forward-Looking Statements.

Key Points: 
  • All information that is not clearly historical in nature may constitute Forward-Looking Statements.
  • Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.
  • SRNG and Ginkgo caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.
  • In connection with the proposed transaction, SRNG filed a Proxy Statement on August 13, 2021 (the "Proxy Statement").

Creo appoints commercial leader Graeme Kenny as Chief Revenue Officer

Retrieved on: 
Wednesday, August 11, 2021
CEO, Health, International, Fermentation, Partnership, Technology, Genomatica, CBGA, CRO, Cannabinoid, SAN, CA, CBG, Marketing, Cosmetics, Fine chemical

SAN DIEGO, CA AUGUST 11, 2021- Creo, an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, today announces that it has appointed Graeme Kenny as Chief Revenue Officer, effective immediately.

Key Points: 
  • SAN DIEGO, CA AUGUST 11, 2021- Creo, an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, today announces that it has appointed Graeme Kenny as Chief Revenue Officer, effective immediately.
  • Graemes role at Creo will be to lead commercial rollout in the new fast emerging category of cannabinoid ingredients.
  • Roy Lipski, CEO and co-founder of Creo, said: Im delighted Graeme has chosen to join Creo to spearhead our commercial activities.
  • Graeme has decades of experience in category creation and commercial development in the cosmetics, personal care and wellness industry.

Creo successfully completes commercial fermentation run

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Academic disciplines, Articles, Roy Lipski, Entheogens, Euphoriants, Metabolism, Cannabinoid, Cannabis, PTC Creo, Creo, Fermentation

San Diego, CA August 4, 2021 Creo , an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, announced today the successful completion of its first commercial fermentation run at 28,000 L scale with performance that exceeded the Companys expectations.

Key Points: 
  • San Diego, CA August 4, 2021 Creo , an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, announced today the successful completion of its first commercial fermentation run at 28,000 L scale with performance that exceeded the Companys expectations.
  • The commercial fermentation produced CBGA which is being processed into finished CBGA and CBG for client sampling and sales.
  • Were pleased with the performance of this commercial fermentation run at 28,000 L, which follows our successful demonstration campaign in January said Creos CEO, Roy Lipski.
  • Creo is an ingredients technology company that produces high quality cannabinoids using the natural process of fermentation.

Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate with Multi-Modal Mechanism of Action in Parkinson’s Disease

Retrieved on: 
Tuesday, February 9, 2021
Food and Drug Administration, United States Public Health Service, CBGA

EHP-102 employs a multi-modal mechanism of action, which may offer a new path to better treatment outcomes.

Key Points: 
  • EHP-102 employs a multi-modal mechanism of action, which may offer a new path to better treatment outcomes.
  • The published scientific paper is titled, Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinsons disease using 6-hydroxydopamine-lesioned mice.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing proprietary product candidates to treat CNS, autoimmune, and other diseases.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.

As market matures central banks conclude that a formal gold agreement is no longer necessary

Retrieved on: 
Monday, July 29, 2019
Economy, Finance, Money, CBGA, Eurozone, Central banks, European System of Central Banks, Gold investments, European Central Bank, Gold as an investment, Bank, Washington Agreement on Gold

PRESS RELEASE

Key Points: 
  • PRESS RELEASE

    As market matures central banks conclude that a formal gold agreement is no longer necessary

    26 July 2019

    The European Central Bank (ECB) and 21 other central banks that are signatories of the Central Bank Gold Agreement (CBGA) have decided not to renew the Agreement upon its expiry in September 2019.

  • The first CBGA was signed in 1999 to coordinate the planned gold sales by the various central banks.
  • When it was introduced, the Agreement contributed to balanced conditions in the gold market by providing transparency regarding the intentions of the signatories.
  • Gold sales within central bank gold agreements(tonnes)

    For media queries, please contact Eva Taylor, tel.